These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20017581)

  • 41. The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic.
    Diak IL; Swank K; McCartan K; Beganovic M; Kidd J; Gada N; Kapoor R; Wolf L; Kangas L; Wyeth J; Salvatore T; Fanari M; LeBoeuf AA; Mishra P; Blum MD; Dal Pan G
    Drug Saf; 2023 Feb; 46(2):145-155. PubMed ID: 36460854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Data gaps in toxicity testing of chemicals allowed in food in the United States.
    Neltner TG; Alger HM; Leonard JE; Maffini MV
    Reprod Toxicol; 2013 Dec; 42():85-94. PubMed ID: 23954440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accessing, using, and creating chemical property databases for computational toxicology modeling.
    Williams AJ; Ekins S; Spjuth O; Willighagen EL
    Methods Mol Biol; 2012; 929():221-41. PubMed ID: 23007432
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Food safety: risk assessment methodology and decision-making criteria.
    Brock WJ; Rodricks JV; Rulis A; Dellarco VL; Gray GM; Lane RW
    Int J Toxicol; 2003; 22(6):435-51. PubMed ID: 14680991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
    Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
    Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory administrative databases in FDA's Center for Biologics Evaluation and Research: convergence toward a unified database.
    Smith JK
    AAPS J; 2013 Apr; 15(2):388-94. PubMed ID: 23269527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Computational analysis for hepatic safety signals of constituents present in botanical extracts widely used by women in the United States for treatment of menopausal symptoms.
    Wang YJ; Dou J; Cross KP; Valerio LG
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):111-24. PubMed ID: 20920542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health effects of toxicants: Online knowledge support.
    Wexler P; Judson R; de Marcellus S; de Knecht J; Leinala E
    Life Sci; 2016 Jan; 145():284-93. PubMed ID: 26506572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systems toxicology.
    Hartung T; van Vliet E; Jaworska J; Bonilla L; Skinner N; Thomas R
    ALTEX; 2012; 29(2):119-28. PubMed ID: 22562485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The safety assessment process--setting the scene: an FDA perspective.
    Schechtman LM
    ILAR J; 2002; 43 Suppl():S5-10. PubMed ID: 12388844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integrating background knowledge from internet databases into predictive toxicology models.
    Edelstein M; Buchwald F; Richter L; Kramer S
    SAR QSAR Environ Res; 2010 Jan; 21(1):21-35. PubMed ID: 20373212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. United States Food and Drug Administration and Department of Defense shelf-life extension program of pharmaceutical products: progress and promise.
    Khan SR; Kona R; Faustino PJ; Gupta A; Taylor JS; Porter DA; Khan M
    J Pharm Sci; 2014 May; 103(5):1331-6. PubMed ID: 24623105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A toxicology ontology roadmap.
    Hardy B; Apic G; Carthew P; Clark D; Cook D; Dix I; Escher S; Hastings J; Heard DJ; Jeliazkova N; Judson P; Matis-Mitchell S; Mitic D; Myatt G; Shah I; Spjuth O; Tcheremenskaia O; Toldo L; Watson D; White A; Yang C
    ALTEX; 2012; 29(2):129-37. PubMed ID: 22562486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comprehension of drug toxicity: software and databases.
    Toropov AA; Toropova AP; Raska I; Leszczynska D; Leszczynski J
    Comput Biol Med; 2014 Feb; 45():20-5. PubMed ID: 24480159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular Similarity in Computational Toxicology.
    Floris M; Olla S
    Methods Mol Biol; 2018; 1800():171-179. PubMed ID: 29934892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities.
    Valencia A; Prous J; Mora O; Sadrieh N; Valerio LG
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):427-34. PubMed ID: 24090816
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Toxicophore exploration as a screening technology for drug design and discovery: techniques, scope and limitations.
    Singh PK; Negi A; Gupta PK; Chauhan M; Kumar R
    Arch Toxicol; 2016 Aug; 90(8):1785-802. PubMed ID: 26341667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.